High-throughput cytochrome P450 cocktail inhibition assay for assessing drug-drug and drug-botanical interactions

Drug Metabolism and Disposition

Volumn 43, Issue 11, 2015, Pages 1670-1678

  Li, Guannan ^a   Huang, Ke ^a   Nikolic, Dejan ^a   Van Breemen, Richard B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; COUMARIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; GLYCYRRHIZA GLABRA EXTRACT; TESTOSTERONE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; ISOENZYME;

ARTICLE; BINDING SITE; ENZYME BINDING; ENZYME INHIBITION ASSAY; ENZYME MECHANISM; ENZYME SUBSTRATE; GLYCYRRHIZA GLABRA; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; IC50; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTON TRANSPORT; TANDEM MASS SPECTROMETRY; VALIDITY; CHEMISTRY; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GLYCYRRHIZA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; LIVER MICROSOME; METABOLISM; PHYSIOLOGY; PROCEDURES;

BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GLYCYRRHIZA; HERB-DRUG INTERACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; TANDEM MASS SPECTROMETRY;

EID: 84946212439     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.065987     Document Type: Article

References (41)

1. Alden PG, Plumb RS, Jones M.D., Rainville PD, and Shave D (2010) A rapid ultra-performance liquid chromatography/tandem mass spectrometric methodology for the in vitro analysis of Pooled and Cocktail cytochrome P450 assays. Rapid Commun Mass Spectrom 24:147-154.
2. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, and Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293.
3. Busby WF, Jr, Ackermann JM, and Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-249.
4. Chatterjee P and Franklin MR (2003) Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31:1391-1397.
5. Chauret N, Gauthier A, and Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4.
6. Davis A and Ward SE (2014) The Handbook of Medicinal Chemistry: Principles and Practice, Royal Society of Chemistry., Cambridge, UK.
7. Dey A (2013) Cytochrome P450 2E1: Its Role in Disease and Drug Metabolism, Springer., Dordrecht, The Netherlands.
8. Dierks EA, Stams KR, Lim H.K., Cornelius G., Zhang H, and Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29.
9. Dinger J, Meyer MR, and Maurer HH (2014) Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett 230: 28-35 Elsevier Ireland Ltd.
10. Eagling VA, Tjia JF, and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
11. Food and Drug Administration (2012). Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing and Labeling Recommendations (Draft). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf.
12. Giancarlo GM, Venkatakrishnan K, Granda B.W., von Moltke LL, and Greenblatt DJ (2001) Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol 57:31-36.
13. Gurley BJ, Gardner SF, Hubbard M.A., Williams DK, Gentry WB, Khan IA, and Shah A (2005) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415-426.
14. He F, Bi HC, Xie Z.Y., Zuo Z., Li JK, Li X, Zhao LZ, Chen X, and Huang M (2007) Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 21:635-643.
15. Jia L and Liu X (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8:822-829.
16. Kent UM, Aviram M, Rosenblat M., and Hollenberg PF (2002) The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 30:709-715.
17. Kim M-J, Kim H., Cha I-J, Park J-S, Shon J-H, Liu K-H, and Shin J-G (2005) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651-2658.
18. Kozakai K, Yamada Y, Oshikata M., Kawase T, Suzuki E, Haramaki Y., and Taniguchi H (2012) Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards. Drug Metab Pharmacokinet 27:520-529.
19. Lee KS and Kim SK (2013) Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions. J Appl Toxicol 33:100-108.
20. Li X, Chen X, Li Q., Wang L, and Zhong D (2007) Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 852:128-137.
21. Liu L, Han Y, Zhu J., Yu Q, and Yang Q (2015) A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates. Biomed Chromatogr 29:437-444.
22. Ogilvie BW, Usuki E, Yerino P., and Parkinson A (2008) In Vitro Approaches for Studying the Inhibition of Drug-Metabolizing Enzymes and Identifying the Drug-Metabolizing Enzymes Responsible for the Metabolism of Drugs (Reaction Phenotyping) with Emphasis on Cytochrome, in Drug-Drug Interactions (Rodrigues DA ed) p 450, Informa Healthcare, New York.
23. Otten JN, Hingorani GP, Hartley D.P., Kragerud SD, and Franklin RB (2011) An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS. Drug Metab Lett 5:17-24.
24. Patki KC, Von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938-944.
25. Pelkonen O, Rautio A, Raunio H., and Pasanen M (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144:139-147.
26. Pratt-Hyatt M., Lin HL, and Hollenberg PF (2010) Mechanism-based inactivation of human CYP2E1 by diethyldithocarbamate. Drug Metab Dispos 38:2286-2292.
27. Qiao X, Ji S, Yu S-W, Lin X-H, Jin H-W, Duan Y-K, Zhang L-R, Guo D-A, and Ye M (2014) Identification of key licorice constituents which interact with cytochrome P450: evaluation by LC/MS/MS cocktail assay and metabolic profiling. AAPS J 16:101-113.
28. Qin C-Z, Ren X., Tan Z-R, Chen Y, Yin J-Y, Yu J, Qu J., Zhou H-H, and Liu Z-Q (2014) A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 28:197-203.
29. Shader RI, Granda BW, von Moltke LL, Giancarlo GM, and Greenblatt DJ (1999) Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. Biopharm Drug Dispos 20:385-388.
30. Sittampalam GS, Gal-Edd N, Arkin M., Sittampalam GS, Coussens NP, Nelson H, Arkin M., Auld D, Austin C, Bejcek B., et al. (2004) Assay Guidance Manual National Center for Biotechnology Information., Bethesda, MD.
31. Smith D, Sadagopan N, Zientek M., Reddy A, and Cohen L (2007) Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J Chromatogr B Analyt Technol Biomed Life Sci 850:455-463.
32. Spaggiari D, Geiser L, Daali Y., and Rudaz S (2014) A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. J Pharm Biomed Anal 101:221-237.
33. Testino SA, Jr and Patonay G (2003) High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 30:1459-1467.
34. Tolonen A, Petsalo A, Turpeinen M., Uusitalo J, and Pelkonen O (2007) In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 42:960-966.
35. Turpeinen M, Nieminen R, Juntunen T., Taavitsainen P, Raunio H, and Pelkonen O (2004) Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 32:626-631.
36. Turpeinen M, Uusitalo J, Jalonen J., and Pelkonen O (2005) Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 24:123-132.
37. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
38. Workman P and Raynaud FI (2007) Analysis of potential drug-drug interactions for anti-cancer agents in human liver microsomes by high throughput liquid chromatography/mass spectrometry assay. Austral-Asian J Cancer 6:55-69.
39. Yao M, Cai H, and Zhu M (2012) Fast and reliable cyp inhibition assays, in ADME-Enabling Technologies in Drug Design and Development (Zhang D and Surapaneni S ed) pp 213-232, John Wiley & Sons, Inc., Hoboken, NJ.
40. Yuan R, Madani S, Wei X-X, Reynolds K, and Huang S-M (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319.
41. Zientek M, Miller H, Smith D., Dunklee MB, Heinle L, Thurston A, Lee C., Hyland R, Fahmi O, and Burdette D (2008) Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 58:206-214.